News Release 29-Jul-2020
The study, published in Nature, shows that sodium controls hypoxic signaling in the mitochondrial respiratory chain
Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.)
Researchers at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) and the Instituto de Investigación Sanitaria Princesa (IIS Princesa) have made a major advance toward deciphering the mechanism through which the production of reactive oxygen species (ROS) increases in the early phases of hypoxia (acute reduction in tissue oxygen). The finding represents an important advance in the understanding of cell physiology and could be exploited in the future to treat a variety of diseases in which hypoxia plays a role, such as stroke and heart attack.
The study, published today in Nature, is the fruit of a partnership between the groups led by Dr Antonio Martínez, at Hospital Santa Cristina (part of the IIS Princesa), and Dr José Antonio Enríquez, at the CNIC. The study was led by Dr Pablo Hernansanz-Agustín, a postdoctoral researcher at the CNIC.
In most eukaryotic cells, energy is generated by the consumption of oxygen in the mitochondrial oxidative phosphorylation (OXPHOS) system. As Dr Enríquez explained, “the consumption of oxygen by this system generates reactive oxygen species (ROS), a group of molecules that until recently were considered to be metabolic toxins.”
However, it is now known that when produced in small amounts, these reactive species act as signals that trigger cell adaptations. In this way, continued Dr Enríquez, “a drop in oxygen concentration triggers the rapid generation of ROS, which initiate the adaptive response of cells to oxygen deficiency.” The 2019 Nobel Prize in Physiology or Medicine was awarded to the scientists who discovered the mechanism by which cells mount a response to sustained hypoxia. This long-term response is mediated by hypoxia-inducible factor (HIF). But the body has other, faster ways to respond to hypoxia that are independent of HIF and are mediated by ROS. The exact mechanism through which ROS production is increased in the early stages of hypoxia is still unclear, but the new study makes an important advance toward defining this process.
“We have shown that sodium ions act as second messengers that regulate mitochondrial function, specifically the function of the mitochondrial electron transport chain (ETC), by inducing the controlled production of ROS,” explained Dr Hernansanz.
This mechanism of ROS production “is fundamental to the ability of the pulmonary circulation to respond to hypoxia by redistributing blood flow to regions with less irrigation, a phenomenon known as hypoxic pulmonary vasoconstriction,” explained Dr Martínez.
Several of the study findings provide important information about cell physiology. First, the study shows that mitochondrial sodium regulates cell membrane fluidity. This was unknown before and could have major implications for the understanding of a multitude of cellular processes.
A second important discovery, explained Dr Enríquez, is that “the mitochondrial supercomplexes of the ETC play an important role in this process by adopting structural conformations that are sensitive or insensitive to sodium, thus ensuring that the action of sodium is nontoxic.”
Dr Martínez added that the entry of sodium is preceded by the solubilization of calcium deposits inside the mitochondria. These calcium structures were first described more than 50 years ago, but their function was unknown until now.
Dr Martínez concluded that “the study shows that inhibition of the mitochondrial Ca2+/Na+ exchanger NCLX is sufficient to block this pathway, preventing hypoxia adaptation.” This finding indicates that NCLX could be a future therapeutic target for diseases in which hypoxia plays a role.
The study results reveal that sodium controls OXPHOS function and cell signaling in hypoxia through an unexpected interaction with phospholipids, with major consequences for cell metabolism.
The study also involved contributions from scientists working at the Centro de Investigación Cooperativa en Biomateriales (CIC biomaGUNE); the Instituto de Investigación Sanitaria Gregorio Marañón (IISGM); the Centro Andaluz de Biología del Desarrollo-Universidad Pablo de Olavide-CSIC (Seville); and the Spanish biomedical research networks (CIBER) in Respiratory Diseases (CIBERES), Rare Diseases (CIBERER), Frailty and Healthy Aging (CIBERFES), and Cardiovascular Disease (CIBERCV).
The study has been funded with grants from The International Human Frontier Science Program Organization (HFSPO) (HFSP RGP0016 / 2018)
About the CNIC
The Centro Nacional de Investigaciones Cardiovasculares (CNIC), directed by Dr. Valentín Fuster, is dedicated to cardiovascular research and the translation of knowledge gained into real benefits for patients. The CNIC, recognized by the Spanish government as a Severo Ochoa center of excellence, is financed through a pioneering public-private partnership between the government (through the Carlos III Institute of Health) and the Pro-CNIC Foundation, which brings together 12 of the most important Spanish private companies.
About IIS Princesa
The IIS Princesa, directed by Dr Francisco Sánchez Madrid, is a research center certified by the Instituto de Salud Carlos III (ISCIII) in 2010. It has its main base in the Hospital Universitario de La Princesa and also includes research groups at the Universidad Autónoma de Madrid and Niño Jesús and Santa Cristina university hospitals, also in Madrid. The IIS Princesa comprises almost 60 research groups, some 30 defined research areas, and more than 400 research scientists.